Registered title, quoted from ClinicalTrials.gov
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 3 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteCancer Hospital CAMS – Shenzhen中国医学科学院肿瘤医院深圳医院ShenzhenHospital page
- Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07689851, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
Inclusion criterion 2
Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies.
Exclusion criterion 2
ECOG performance status of 0-1.
Inclusion criterion 5
Hemoglobin ≥90 g/L;
Inclusion criterion 8
Absolute neutrophil count ≥1.5 × 10⁹/L;
Inclusion criterion 10
Platelet count ≥100 × 10⁹/L;
Inclusion criterion 11
Serum creatinine ≤1.0 × upper limit of normal (ULN);
Inclusion criterion 12
Blood urea nitrogen (BUN) ≤1.0 × ULN;
Inclusion criterion 13
Alanine aminotransferase (ALT) ≤1.5 × ULN;
Inclusion criterion 14
Aspartate aminotransferase (AST) ≤1.5 × ULN;
Inclusion criterion 15
Alkaline phosphatase (ALP) ≤1.5 × ULN;
Inclusion criterion 16
Total bilirubin (TBIL) ≤1.5 × ULN;
Inclusion criterion 17
At least one measurable lesion according to RECIST version 1.1.
Inclusion criterion 6
Congenital or acquired immunodeficiency, including HIV infection, or a history of organ transplantation or allogeneic hematopoietic stem cell transplantation.
Exclusion criterion 10
Active hepatitis B infection (HBV DNA ≥2,000 IU/mL), active hepatitis C infection, or active tuberculosis.
Exclusion criterion 11
Pregnant or breastfeeding women.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07689851, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female participants aged 18 to 75 years.
- Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
- Unresectable locally advanced or metastatic gastric cancer, with primary and metastatic lesions amenable to radiotherapy (excluding patients with brain metastases or extensive metastatic disease).
- HER2-negative disease.
- ECOG performance status of 0-1.
- At least one measurable lesion according to RECIST version 1.1.
- Adequate organ function, including:
- Hemoglobin ≥90 g/L;
- White blood cell count ≥3.5 × 10⁹/L;
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥100 × 10⁹/L;
- Serum creatinine ≤1.0 × upper limit of normal (ULN);
- Blood urea nitrogen (BUN) ≤1.0 × ULN;
- Alanine aminotransferase (ALT) ≤1.5 × ULN;
- Aspartate aminotransferase (AST) ≤1.5 × ULN;
- Alkaline phosphatase (ALP) ≤1.5 × ULN;
- Total bilirubin (TBIL) ≤1.5 × ULN;
- Negative urine protein;
- Normal coagulation function.
- No contraindications to immunotherapy.
- No history of hypersensitivity to fluoropyrimidines or platinum-based agents.
- No prior surgery, chemotherapy, immunotherapy, or other antitumor therapy for gastric or gastroesophageal junction cancer since diagnosis.
- No previous radiotherapy to the intended irradiation sites.
- Ability to understand and willingness to sign a written informed consent form.
Exclusion Criteria:
- Brain metastases or extensive metastatic disease.
- Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies.
- Severe autoimmune diseases, including but not limited to active inflammatory bowel disease (Crohn's disease or ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or autoimmune vasculitis (e.g., Wegener's granulomatosis).
- Symptomatic interstitial lung disease or active infectious/non-infectious pneumonitis.
- Conditions associated with an increased risk of gastrointestinal perforation, including active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis, or other known risk factors.
- History of another malignancy, except adequately treated early-stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
- Active infection, heart failure, myocardial infarction within 6 months, unstable angina, or unstable cardiac arrhythmia.
- Any physical examination findings, laboratory abnormalities, or uncontrolled medical conditions that, in the investigator's judgment, may interfere with study outcomes or increase the risk of treatment-related complications.
- Pregnant or breastfeeding women.
- Congenital or acquired immunodeficiency, including HIV infection, or a history of organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Active hepatitis B infection (HBV DNA ≥2,000 IU/mL), active hepatitis C infection, or active tuberculosis.
- Receipt of any live or other prohibited vaccines within 4 weeks before study treatment. Seasonal inactivated influenza vaccines are permitted, whereas intranasal live attenuated influenza vaccines are not permitted.
- Concurrent treatment with other immunosuppressive agents, chemotherapy, investigational drugs, or long-term systemic corticosteroids.
- Psychiatric disorders, substance abuse, or social conditions that may compromise treatment compliance, as determined by the investigator.
- Known hypersensitivity or contraindication to any study treatment.
Quoted from ClinicalTrials.gov, NCT07689851, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07689851, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.